

# DON AGRO INTERNATIONAL LIMITED

Registration No. 201835258H  
(Incorporated in the Republic of Singapore)

---

## 1) MONTHLY VALUATION OF ASSETS AND UTILISATION OF CASH FOR THE MONTH OF DECEMBER 2025; AND

## 2) UPDATE OF MILESTONES IN OBTAINING NEW BUSINESS

---

The Board of Directors (the “**Board**” or the “**Directors**”) of Don Agro International Limited (the “**Company**”) refers to the announcement released on the SGXNet on 8 July 2024 notifying shareholders of its cash company status pursuant to Rule 1017(1)(a) of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) Listing Manual Section B: Rules of Catalist (the “**Catalist Rules**”) and its previous announcement dated 29 January 2026 on the monthly updates.

Pursuant to Catalist Rule 1017(1)(b), the Board wishes to announce the following:

### 1. MONTHLY VALUATION OF ASSETS AND UTILISATION OF CASH FOR THE MONTH OF DECEMBER 2025

a) The Company’s assets and liabilities as at 31 December 2025 were as follows:

|                             | <u>\$’000</u> |
|-----------------------------|---------------|
| <b><u>Assets</u></b>        |               |
| Long-term investment        | 662           |
| Trade and other receivables | 43,722        |
| Cash and cash equivalents   | <u>24,679</u> |
| <b>Total assets</b>         | <u>69,063</u> |
| <b><u>Liabilities</u></b>   |               |
| Trade and other payables    | 1,741         |
| Current tax liabilities     | 86            |
| Provisions                  | <u>39</u>     |
| <b>Total liabilities</b>    | <u>1,866</u>  |
| <b>Net assets</b>           | 67,197        |

(b) The Company’s utilisation of cash from 1 December 2025 to 31 December 2025 was as follows:

|  | <u>RR’000<sup>1 &amp; 2</sup></u> | <u>\$’000</u> |
|--|-----------------------------------|---------------|
| Opening cash and bank balances as at 1 November 2025 | 1,508,582                         | 25,304        |
| Add receipts:  |                                   |               |
| Interest income from deposit                         | 8                                 | -             |
| Receipts from loan receivable                        | 25,000                            | 410           |
| Foreign currency translation adjustment              | -                                 | <u>(603)</u>  |
| <b>Total receipts</b>                                | <u>25,008</u>                     | <u>(193)</u>  |
| Less payments:                                       |                                   |               |
| Bank charges and miscellaneous                       | <u>(120)</u>                      | <u>(2)</u>    |

<sup>1</sup> Relates to Russian subsidiaries of the Company and does not relate to the Company

<sup>2</sup> RR 59.72 to \$ 1 as at 1 December 2025; RR 60.91 to \$ 1 for December 2025; RR 61.50 to \$ 1 as at 31 December 2025.

|  |                  |               |
|--|------------------|---------------|
| General and administrative expenses                          | (25,182)         | (430)         |
| <b>Total payments</b>  | <b>(25,302)</b>  | <b>(432)</b>  |
| <b>Closing cash and bank balances as at 31 December 2025</b> | <b>1,508,288</b> | <b>24,679</b> |

All figures set out in this announcement have not been reviewed or audited by the Company's auditors.

## 2. UPDATE OF MILESTONES IN OBTAINING A NEW BUSINESS

As mentioned in the announcement dated 12 September 2024 in relation to the proposed acquisition of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC (the "**Proposed Acquisition Announcement**"), that JSC Tetra, a wholly-owned subsidiary of the Company had, on 6 September 2024, entered into the agreements in respect of the proposed acquisition of 99.99% of the shares in 812 Capital LLC and 11.50% of the shares in Centre for Innovative Medical Technologies, LLC (together with their respective subsidiaries, the "**Target Group**").

The Target Group is a Russian network of expert oncology clinics operating under the "Euroonco" brand that provide a full range of cancer diagnostics and treatment. Entities operating under the Euroonco brand, focus primarily on providing a full range of cancer diagnostics and treatment services, as well as all types of antitumor and palliative treatment. Euroonco has expert oncology clinics and information and service centres in Moscow, Saint Petersburg and Krasnodar. Please refer to the Proposed Acquisition Announcement for further details.

On 30 December 2025 the Circular in relation to the proposed acquisition of 812 Capital LLC and Centre for Innovative Medical Technologies, LLC by JSC Tetra being a very substantial acquisition under the Catalist Rules of SGX-ST have been released onto SGXNet. On 28 January 2026, shareholders have approved the proposed acquisition of healthcare assets (the "**Proposed Acquisitions**"), the diversification of the Group's core business into healthcare and the proposed change of the Company's name to "UpHealth Group Limited" at the Extraordinary general meeting ("**EGM**") held on 28 January 2026.

On 2 January 2026, the Company submitted an application to the SGX-ST through its continuing sponsor and financial adviser to the Company for the Proposed Acquisitions, PPCF, for a further 3-month extension to the 12-month period for the Company to meet the requirements for a new listing under Rule 1017(2) of the Catalist Rules.

On 21 January 2026, the Company received a letter from the SGX-ST advising that the SGX-ST has no objections to the Company's application for the Second Extension, subject to the extension conditions being satisfied. For further details, please refer to the Company's announcement dated 23 January 2026.

There are no other updates of milestones in obtaining new business for December 2025 and Company is still now working towards completing the Proposed Acquisitions.

### BY ORDER OF THE BOARD

**Marat Devlet-Kildeev**  
**Chief Executive Officer and Executive Director**  
31 January 2026

---

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, [sponsorship@ppcf.com.sg](mailto:sponsorship@ppcf.com.sg).